Browse > Article
http://dx.doi.org/10.3345/kjp.2009.52.8.938

Effect of renin inhibition on an experimental glomerulonephritis - a preliminary report  

Kang, Ju-Hyung (Department of Pediatrics, College of Medicine, Eulji University)
Heo, Jae-Kyung (Department of Pediatrics, College of Medicine, Eulji University)
Lee, Young-Sook (Department of Internal Medicine, College of Medicine, Eulji University)
Han, Ji-Young (Clinical Research Institute, Seoul National University Hospital)
Ha, Il-Soo (Department of Pediatrics, College of Medicine, Seoul National University)
Publication Information
Clinical and Experimental Pediatrics / v.52, no.8, 2009 , pp. 938-943 More about this Journal
Abstract
Purpose : We performed this study in order to investigate the effect of direct renin inhibition on an experimental animal model with nephrotoxic serum nephritis and tried to give useful information for clinical research and renin inhibitor treatment. Methods : Thirty BALB/c 6-week-old male mice were divided into 4 groups: control group (CO, n=5), control-treatment group with aliskiren (CT, n=5), disease group (DO, n=10), and disease treatment group with aliskiren (DT, n=10). Nephritis was induced by an intravenous injection of 0.25 mg/g weight of rabbit anti-GBM immunoglobulin G. Model 2002 Alzet mini-osmotic pumps (Durect Corp.) for aliskiren infusion were implanted into CT and DT. Each group strain was sacrificed serially one at a time on day 14. We estimated the protein-creatinine ratio in 12-hour-collected urine (UP/Cr) and measured the mesangial matrix score in the PAS-stained kidney of each strain. Results : One strain at CT and DT died on day 6 and 7, respectively. Each group strain was sacrificed serially at a time on day 10 because DO were seriously ill. The UP/Cr of each group is as follows: CO, $31.24{\pm}6.54mg/mg$, CT, $23.38{\pm}13.60mg/mg$, DO, $112.72{\pm}10.97mg/mg$, DT $114.07{\pm}32.30mg/mg$. There was no significant difference between DO and DT. The mesangial matrix score of each group was CO, $0.23{\pm}0.10$; CT, $0.13{\pm}0.03$; DO, $1.90{\pm}0.48$; and DT, $1.28{\pm}0.41$, respectively, and there was a significant difference between DO and DT in the extent of mesangial matrix expansion (P=0.008). Conclusion : We found that renin inhibition was able to suppress the mesangial matrix expansion in experimental mice with acute nephritis, although there were no significant differences in UP/Cr.
Keywords
Renin inhibition; Urine protein-creatinine ratio; Acute glomerular basement membrane nephritis;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Rongen GA, Lenders JW, Smits P, Thien T. Clinical pharmacokinetics and efficacy of renin inhibitors. Clin Pharmacokinet 1995;29:6-14   DOI   ScienceOn
2 Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM et al. Acute angiotensin converting enzyme inhibition increases the plasma level of the natural stem-cell regulator N-Acetyl-Seryl-Aspartyl-Lysyl-Proline. J Clin Invest 1996;97:839-44   DOI
3 Yayama K, Matsui T, Takano M, Hayashi K, Nagamatsu T, Suzuki Y, et al. Activation of the renin-angiotensin system in anti-glomerular basement membrane antibody-induced glomerulonephritis. Biol Pharm Bull 1995;18:411-5   DOI   PUBMED   ScienceOn
4 Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012-8   DOI   ScienceOn
5 Karlberg BE. Cough and inhibition of the renin-angiotensin system. J Hypertens 1993;11:S49-S52   DOI
6 Hong L, Rateri DL, Feldman DL, Charnigo RJ, Fukamizu A, Ishida J, et al. Renin inhibition reduces hypercholesterolemia- induced atherosclerosis in mice. J clin Invest 2008;118:984-93   ScienceOn
7 Todd PA, Heel RC. Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1986;31: 198-248   DOI   ScienceOn
8 Stanton A. Potential of renin inhibition in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2003;4:6-10   DOI   ScienceOn
9 Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 2003;24:261-71   DOI   ScienceOn
10 Rahuel J, Rasetti V, Maibaum J, Rueger H, Goschke R, Cohen NC, et al. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol 2000;7:493-504   DOI   ScienceOn
11 Kagami S, Border WA, Ruoslahti E, Noble NA. Coordinated expression of beta 1 integrins and transforming growth factor-β induced matrix proteins in glomerulonephritis. Lab Invest 1993;69:68-76   ScienceOn
12 Yoo TH, Ryu DR, Lee JJ, Kim JJ, Jung DS, Kwak SJ, et al. The effect of high glucose on renin-angiotensin system (RAS) in podocytes. Korean J Nephrol 2006;25:903-12
13 Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, et al. Renin increases mesangial cell transforming growth factor-β1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kid Int 2006;69:105-13   DOI   ScienceOn
14 Salant DJ, Cybulsky AV: Experimental glomerulonephritis. Method Enzymol 1988;162:421-61
15 Zhao Y, Biermann T, Luther C, Unger T, Culman J, Gohlke P. Contribution of bradykinin and nitric oxide to AT2 receptor-mediated differentiation in PC12 W cells. J Neurochem 2003;85:759-67   DOI   PUBMED   ScienceOn
16 Hernandez R, Sosa-Canache B, Velasco M, Armas-Hernandez MJ. Armas-Padilla MC, Cammarata R. Angiotensin II receptor antagonists role in arterial hypertension. J Hum Hypertens 2002;16(Suppl 1):S93-9   ScienceOn
17 Nguyen G, Burckle C, Sraer JD. The renin receptor: the facts, the promise and the hope. Curr Opin Nephrol Hypertens 2003;12:51-5   DOI   ScienceOn
18 Fisher ND, Hollenberg N. Renal vascular responses to renin inhibition with zankiren in men. Clin Pharmacol Ther 1995; 57:342-8   DOI   ScienceOn
19 Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin (1-7): an evolving story in cardiovascular regulation. Hypertension 2006;47:515-21   DOI   PUBMED   ScienceOn
20 Mezzano SA. Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 2001;38:635-8   DOI   ScienceOn
21 Michel A. Direct renin inhibition:clinical pharmacology. J Mol Med 2008;86:647-54   DOI   ScienceOn
22 Dzau VJ. Theodore Cooper lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001;37:1047-52   PUBMED   ScienceOn
23 Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004;109:2492-9   DOI   ScienceOn
24 Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148:30-48   DOI   PUBMED
25 Kim JH, Ha IS, Hwang CI, Lee YJ, Kim JH, Yang SH, et al. Gene expression profiling of anti-GBM glomerulonephritis model: The role of NF-κB in immune complex kidney disease. Kid Int 2004;66:1826-37   DOI   ScienceOn
26 Ibrahim MM. RAS inhibition in hypertension. J Hum Hypertens 2006;20:101-8   DOI   PUBMED   ScienceOn